Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACBFF NASDAQ:GMAB OTCMKTS:GNMSF NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$5.05+4.3%$4.80$2.20▼$12.53$4.85BN/A4.22 million shs932,988 shsGMABGenmab A/S$27.73-0.4%$23.10$17.24▼$28.03$17.79B0.931.45 million shs1.22 million shsGNMSFGenmab A/S$277.60+1.1%$227.94$170.00▼$277.66$18.34B0.9250 shs10 shsSMMTSummit Therapeutics$17.60-6.5%$25.67$15.55▼$36.91$13.07B-1.023.73 million shs12.59 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis-1.43%-10.70%+8.04%-18.66%-10.54%GMABGenmab A/S+1.05%+7.49%+29.86%+22.98%+1.35%GNMSFGenmab A/S+1.13%+11.37%+28.33%+23.76%-0.42%SMMTSummit Therapeutics-3.14%-21.02%-34.30%-3.83%-1.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$5.05+4.3%$4.80$2.20▼$12.53$4.85BN/A4.22 million shs932,988 shsGMABGenmab A/S$27.73-0.4%$23.10$17.24▼$28.03$17.79B0.931.45 million shs1.22 million shsGNMSFGenmab A/S$277.60+1.1%$227.94$170.00▼$277.66$18.34B0.9250 shs10 shsSMMTSummit Therapeutics$17.60-6.5%$25.67$15.55▼$36.91$13.07B-1.023.73 million shs12.59 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis-1.43%-10.70%+8.04%-18.66%-10.54%GMABGenmab A/S+1.05%+7.49%+29.86%+22.98%+1.35%GNMSFGenmab A/S+1.13%+11.37%+28.33%+23.76%-0.42%SMMTSummit Therapeutics-3.14%-21.02%-34.30%-3.83%-1.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACBFFAurora Cannabis 0.00N/AN/AN/AGMABGenmab A/S 2.64Moderate Buy$37.6035.59% UpsideGNMSFGenmab A/S 0.00N/AN/AN/ASMMTSummit Therapeutics 2.65Moderate Buy$33.7991.86% UpsideCurrent Analyst Ratings BreakdownLatest ACBFF, SMMT, GMAB, and GNMSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/27/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $50.008/19/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.008/19/2025GMABGenmab A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/19/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.008/18/2025SMMTSummit TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$21.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACBFFAurora CannabisN/AN/AN/AN/AN/AN/AGMABGenmab A/S$3.26B5.46$1.53 per share18.16$8.04 per share3.45GNMSFGenmab A/S$3.12B5.87$15.35 per share18.08$80.53 per share3.45SMMTSummit Therapeutics$700K18,687.98N/AN/A$0.53 per share33.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACBFFAurora CannabisN/A$0.1242.08∞N/AN/AN/AN/AN/AGMABGenmab A/S$1.14B$1.9913.9315.581.6137.53%21.03%16.98%11/5/2025 (Estimated)GNMSFGenmab A/S$1.14B$19.9213.94∞N/A37.53%21.03%16.98%11/6/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest ACBFF, SMMT, GMAB, and GNMSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/7/2025Q2 2025GNMSFGenmab A/S$3.99$5.42+$1.43$5.42$949.06 million$925.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACBFFAurora CannabisN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACBFFAurora CannabisN/AN/AN/AGMABGenmab A/SN/A6.226.20GNMSFGenmab A/SN/A6.226.20SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACBFFAurora CannabisN/AGMABGenmab A/S7.07%GNMSFGenmab A/SN/ASMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipACBFFAurora CannabisN/AGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACBFFAurora Cannabis1,340960.96 millionN/ANot OptionableGMABGenmab A/S2,682641.59 million631.71 millionOptionableGNMSFGenmab A/S2,68266.08 million65.06 millionNot OptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableACBFF, SMMT, GMAB, and GNMSF HeadlinesRecent News About These CompaniesSummit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions2 hours ago | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT5 hours ago | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedSeptember 10 at 1:54 PM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 10 at 9:59 AM | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at HC WainwrightSeptember 10 at 8:51 AM | marketbeat.comCORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 9 at 12:43 AM | globenewswire.comSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.September 9 at 3:35 PM | globenewswire.comSMMT Stock Plummets 25% on Regional Data Differences in NSCLC StudySeptember 9 at 2:21 PM | zacks.comPolar Asset Management Partners Inc. Trims Holdings in Summit Therapeutics PLC $SMMTSeptember 9 at 5:21 AM | marketbeat.com538,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Adage Capital Partners GP L.L.C.September 9 at 4:15 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Given Overweight Rating at Cantor FitzgeraldSeptember 9 at 2:57 AM | americanbankingnews.comSummit Therapeutics falls -24.1%September 8 at 12:33 AM | msn.comSummit Therapeutics (SMMT) WCLC Update Call (Transcript)September 8 at 4:18 PM | seekingalpha.comSummit Therapeutics (SMMT) WCLC Update CallSeptember 8 at 3:36 PM | seekingalpha.comSummit Therapeutics shares fall as lung cancer trial results disappointSeptember 8 at 12:36 PM | proactiveinvestors.comIvonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332September 7 at 6:08 AM | prnewswire.comLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in ...September 7 at 5:08 AM | finance.yahoo.comVident Advisory LLC Acquires Shares of 41,183 Summit Therapeutics PLC $SMMTSeptember 7 at 4:29 AM | marketbeat.comLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLCSeptember 7 at 3:30 AM | businesswire.comCutter Capital Management LP Invests $7.72 Million in Summit Therapeutics PLC $SMMTSeptember 6, 2025 | marketbeat.comSummit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT)September 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACBFF, SMMT, GMAB, and GNMSF Company DescriptionsAurora Cannabis OTCMKTS:ACBFF$5.05 +0.21 (+4.34%) As of 09/9/2025Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.Genmab A/S NASDAQ:GMAB$27.73 -0.10 (-0.36%) Closing price 04:00 PM EasternExtended Trading$27.76 +0.02 (+0.09%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$277.60 +3.10 (+1.13%) As of 09/9/2025 09:32 AM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Summit Therapeutics NASDAQ:SMMT$17.60 -1.23 (-6.53%) Closing price 04:00 PM EasternExtended Trading$17.42 -0.18 (-1.02%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
